245 related articles for article (PubMed ID: 19345151)
1. Clonal expansion of B-cells in human systemic lupus erythematosus: evidence from studies before and after therapeutic B-cell depletion.
Sfikakis PP; Karali V; Lilakos K; Georgiou G; Panayiotidis P
Clin Immunol; 2009 Jul; 132(1):19-31. PubMed ID: 19345151
[TBL] [Abstract][Full Text] [Related]
2. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus.
Anolik JH; Barnard J; Cappione A; Pugh-Bernard AE; Felgar RE; Looney RJ; Sanz I
Arthritis Rheum; 2004 Nov; 50(11):3580-90. PubMed ID: 15529346
[TBL] [Abstract][Full Text] [Related]
3. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.
Lindholm C; Börjesson-Asp K; Zendjanchi K; Sundqvist AC; Tarkowski A; Bokarewa M
J Rheumatol; 2008 May; 35(5):826-33. PubMed ID: 18398943
[TBL] [Abstract][Full Text] [Related]
4. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy.
Anolik JH; Barnard J; Owen T; Zheng B; Kemshetti S; Looney RJ; Sanz I
Arthritis Rheum; 2007 Sep; 56(9):3044-56. PubMed ID: 17763423
[TBL] [Abstract][Full Text] [Related]
5. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab.
Looney RJ; Anolik JH; Campbell D; Felgar RE; Young F; Arend LJ; Sloand JA; Rosenblatt J; Sanz I
Arthritis Rheum; 2004 Aug; 50(8):2580-9. PubMed ID: 15334472
[TBL] [Abstract][Full Text] [Related]
6. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus.
Albert D; Dunham J; Khan S; Stansberry J; Kolasinski S; Tsai D; Pullman-Mooar S; Barnack F; Striebich C; Looney RJ; Prak ET; Kimberly R; Zhang Y; Eisenberg R
Ann Rheum Dis; 2008 Dec; 67(12):1724-31. PubMed ID: 18250115
[TBL] [Abstract][Full Text] [Related]
7. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response.
Cambridge G; Isenberg DA; Edwards JC; Leandro MJ; Migone TS; Teodorescu M; Stohl W
Ann Rheum Dis; 2008 Jul; 67(7):1011-6. PubMed ID: 17962238
[TBL] [Abstract][Full Text] [Related]
8. Comparable heavy and light chain pairings in normal and systemic lupus erythematosus IgG(+) B cells.
de Wildt RM; Tomlinson IM; van Venrooij WJ; Winter G; Hoet RM
Eur J Immunol; 2000 Jan; 30(1):254-61. PubMed ID: 10602048
[TBL] [Abstract][Full Text] [Related]
9. B-cell depletion for autoimmune thrombocytopenia and autoimmune hemolytic anemia in pediatric systemic lupus erythematosus.
Kumar S; Benseler SM; Kirby-Allen M; Silverman ED
Pediatrics; 2009 Jan; 123(1):e159-63. PubMed ID: 19074962
[TBL] [Abstract][Full Text] [Related]
10. A longitudinal analysis of SLE patients treated with rituximab (anti-CD20): factors associated with B lymphocyte recovery.
Sutter JA; Kwan-Morley J; Dunham J; Du YZ; Kamoun M; Albert D; Eisenberg RA; Luning Prak ET
Clin Immunol; 2008 Mar; 126(3):282-90. PubMed ID: 18226586
[TBL] [Abstract][Full Text] [Related]
11. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE.
Vallerskog T; Gunnarsson I; Widhe M; Risselada A; Klareskog L; van Vollenhoven R; Malmström V; Trollmo C
Clin Immunol; 2007 Jan; 122(1):62-74. PubMed ID: 17046329
[TBL] [Abstract][Full Text] [Related]
12. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment.
Smith KG; Jones RB; Burns SM; Jayne DR
Arthritis Rheum; 2006 Sep; 54(9):2970-82. PubMed ID: 16947528
[TBL] [Abstract][Full Text] [Related]
13. Phenotypic changes of lymphocytes in patients with systemic lupus erythematosus who are in longterm remission after B cell depletion therapy with rituximab.
Iwata S; Saito K; Tokunaga M; Yamaoka K; Nawata M; Yukawa S; Hanami K; Fukuyo S; Miyagawa I; Kubo S; Tanaka Y
J Rheumatol; 2011 Apr; 38(4):633-41. PubMed ID: 21159836
[TBL] [Abstract][Full Text] [Related]
14. The V(lambda)-J(lambda) repertoire of patients with systemic lupus erythematosus manifests characteristics of the natural antibody repertoire.
Lee J; Cho YJ; Lipsky PE
Arthritis Rheum; 2004 Aug; 50(8):2604-14. PubMed ID: 15334475
[TBL] [Abstract][Full Text] [Related]
15. Regeneration of the immunoglobulin heavy-chain repertoire after transient B-cell depletion with an anti-CD20 antibody.
Rouzière AS; Kneitz C; Palanichamy A; Dörner T; Tony HP
Arthritis Res Ther; 2005; 7(4):R714-24. PubMed ID: 15987473
[TBL] [Abstract][Full Text] [Related]
16. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus.
Marks SD; Patey S; Brogan PA; Hasson N; Pilkington C; Woo P; Tullus K
Arthritis Rheum; 2005 Oct; 52(10):3168-74. PubMed ID: 16200620
[TBL] [Abstract][Full Text] [Related]
17. Lack of deleterious somatic mutations in the CD95 gene of plasmablasts from systemic lupus erythematosus patients and autoantibody-producing cell lines.
Kurth J; Perniok A; Schmitz R; Iking-Konert C; Chiorazzi N; Thompson KM; Winkler T; Rajewsky K; Küppers R
Eur J Immunol; 2002 Dec; 32(12):3785-92. PubMed ID: 12516573
[TBL] [Abstract][Full Text] [Related]
18. B cell depletion therapy for 19 patients with refractory systemic lupus erythematosus.
Podolskaya A; Stadermann M; Pilkington C; Marks SD; Tullus K
Arch Dis Child; 2008 May; 93(5):401-6. PubMed ID: 18039744
[TBL] [Abstract][Full Text] [Related]
19. The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus.
Huang W; Sinha J; Newman J; Reddy B; Budhai L; Furie R; Vaishnaw A; Davidson A
Arthritis Rheum; 2002 Jun; 46(6):1554-62. PubMed ID: 12115186
[TBL] [Abstract][Full Text] [Related]
20. Anti-CD20 monoclonal antibody in rheumatoid arthritis and systemic lupus erythematosus.
Goldblatt F; Isenberg DA
Handb Exp Pharmacol; 2008; (181):163-81. PubMed ID: 18071946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
